Mylan Accuses Teva of Scheme to Delay Generic Version of MS Drug

Mylan Pharmaceuticals Inc. hit rival Teva Pharmaceutical Industries Ltd. with federal antitrust claims in Newark, N.J., on Tuesday over its alleged “comprehensive and sophisticated scheme” to delay generic versions of its multiple sclerosis drug Copaxone.

The lawsuit accuses Teva of lying to doctors about the efficacy of generic Copaxone, covering Medicare copays by laundering kickbacks through charities, and reaching exclusive deals that prohibit pharmacy benefit managers from carrying generics like Mylan’s in their formularies.

Teva also allegedly pushed the health-care industry to shift to a larger standard dose—in an effort to render generics obsolete—and abused the regulatory process through repeat ...